Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EBIT (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed EBIT for 11 consecutive years, with $185.0 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 332.97% to $185.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $447.1 million through Dec 2025, up 178.69% year-over-year, with the annual reading at $447.1 million for FY2025, 178.69% up from the prior year.
  • EBIT for Q4 2025 was $185.0 million at BeOne Medicines, up from $163.1 million in the prior quarter.
  • The five-year high for EBIT was $190.6 million in Q4 2021, with the low at -$474.8 million in Q2 2021.
  • Average EBIT over 5 years is -$189.7 million, with a median of -$197.7 million recorded in 2023.
  • The sharpest move saw EBIT plummeted 731.76% in 2022, then skyrocketed 332.97% in 2025.
  • Over 5 years, EBIT stood at $190.6 million in 2021, then plummeted by 345.92% to -$468.6 million in 2022, then rose by 18.1% to -$383.8 million in 2023, then surged by 79.31% to -$79.4 million in 2024, then surged by 332.97% to $185.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $185.0 million, $163.1 million, and $87.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.